Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Self-evolving AI is no longer a distant concept, as demonstrated by MiniMax M2.7’s remarkable ability to improve itself without human input. By using iterative self-assessment cycles, this model ...
AMD’s Ryzen AI Max+ 395 Strix Halo processor packs a lot of power into a mobile chip designed for laptops and mini PCs. With integrated graphics that rivals a discrete GPU, it offers an efficient ...
SHANGHAI: Two Chinese artificial intelligence (AI) startups seen as possible rivals to OpenAI aim to complete their Hong Kong initial public offerings (IPOs) in the coming weeks. Shanghai-based ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results